ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer

A. Matikas; M. Lambertini

doi:10.1016/j.esmoop.2020.100014

ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer

A. Matikas, M. Lambertini

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	100014
Journal	ESMO Open
Volume	6
Issue number	1
DOIs	https://doi.org/10.1016/j.esmoop.2020.100014
Publication status	Published - Feb 2021

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.esmoop.2020.100014

Cite this

@article{072c4127f80849e79943cb0ec863fcf2,

title = "ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer",

author = "A. Matikas and M. Lambertini",

note = "Funding Information: None declared. AM has no conflicts of interest to disclose. ML acted as a consultant for Roche, Novartis, Lilly and AstraZeneca, and received honoraria from Theramex, Takeda, Roche, Lilly, Pfizer, Novartis and Sandoz outside the submitted work. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = feb,

doi = "10.1016/j.esmoop.2020.100014",

language = "English",

volume = "6",

journal = "ESMO Open",

issn = "2059-7029",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - ESMO20 YO for YO

T2 - highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer

AU - Matikas, A.

AU - Lambertini, M.

N1 - Funding Information: None declared. AM has no conflicts of interest to disclose. ML acted as a consultant for Roche, Novartis, Lilly and AstraZeneca, and received honoraria from Theramex, Takeda, Roche, Lilly, Pfizer, Novartis and Sandoz outside the submitted work. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/2

Y1 - 2021/2

UR - http://www.scopus.com/inward/record.url?scp=85100644080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100644080&partnerID=8YFLogxK

U2 - 10.1016/j.esmoop.2020.100014

DO - 10.1016/j.esmoop.2020.100014

M3 - Article

C2 - 33399079

AN - SCOPUS:85100644080

SN - 2059-7029

VL - 6

JO - ESMO Open

JF - ESMO Open

IS - 1

M1 - 100014

ER -

ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this